targocid teicoplanin lyophilized powder for intravenous infusion 200mg per bottle per box

Description

Indication & Scope

Targocid® is a prescription glycopeptide antibiotic indicated for the treatment of serious infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), enterococci, and streptococci. It is used for skin and soft tissue infections, lower respiratory tract infections, urinary tract infections, bone and joint infections, septicemia, infective endocarditis, and peritoneal dialysis-associated peritonitis. It is also indicated for prophylaxis of Gram-positive infections in selected orthopedic surgery and may be administered orally for Clostridioides difficile-associated pseudomembranous colitis.

Mechanism: Teicoplanin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cell wall formation and leading to bacterial cell death.
Drug Class: Glycopeptide antibiotic.
Clinical Use: Treatment of severe Gram-positive bacterial infections, particularly MRSA and other resistant organisms, and prophylaxis in selected orthopedic procedures.

Specification

Generic Name	Teicoplanin for Injection
Brand Name	Targocid®
Ingredient	Teicoplanin
Dosage Form	Lyophilized Powder for Injection
Package	200 mg/vial/box
Conditions Treated	Severe Gram-positive bacterial infections including MRSA, enterococcal infections, septicemia, infective endocarditis, bone and joint infections, skin and soft tissue infections, respiratory tract infections, urinary tract infections, and peritonitis
Taboos	Hypersensitivity to teicoplanin or other glycopeptide antibiotics
Place of origin	Italy
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 25°C in a dry place, protected from light.
Manufacturer	Sanofi S.r.l.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	HJ20160586
Approval Date	August 1, 2023
Shelf Life	36 months

How to use ?

Recommended Dose: Adults generally receive a loading dose of 400 mg every 12 hours for three doses, followed by a maintenance dose of 200–400 mg once daily depending on the severity of infection. Pediatric dosing is weight-based, and dosage adjustment is recommended in patients with severe renal impairment.

Time: Administer by slow intravenous injection, intravenous infusion over approximately 30 minutes, or deep intramuscular injection when appropriate.

Instructions for use: Reconstitute the vial according to the prescribing information before administration. Therapeutic drug monitoring is recommended during prolonged treatment or in patients with renal impairment to optimize efficacy and minimize toxicity.

Interaction: Concurrent use with aminoglycosides, amphotericin B, cyclosporine, cisplatin, or other nephrotoxic or ototoxic agents may increase the risk of kidney injury or hearing impairment and requires careful monitoring.

Side effects: Common adverse reactions include injection-site reactions, rash, pruritus, nausea, elevated liver enzymes, and headache. Serious adverse reactions include hypersensitivity reactions, nephrotoxicity, ototoxicity, thrombocytopenia, and severe cutaneous adverse reactions.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What infections is Targocid® used to treat?

It is used to treat severe Gram-positive bacterial infections, including MRSA, bloodstream infections, infective endocarditis, bone and joint infections, respiratory tract infections, urinary tract infections, and skin and soft tissue infections.

Can Targocid® be used for MRSA?

Yes. Teicoplanin is active against methicillin-resistant Staphylococcus aureus (MRSA) and is commonly used when resistant Gram-positive infections are suspected or confirmed.

Does teicoplanin require therapeutic drug monitoring?

Yes. Monitoring trough concentrations is recommended for severe infections, prolonged therapy, or patients with renal impairment to ensure adequate drug exposure and reduce toxicity.

Can Targocid® be used in patients allergic to penicillin?

Yes. It is often considered an alternative for patients with serious Gram-positive infections who cannot receive β-lactam antibiotics because of allergy.